Skip to main content

Innocare Pharma

InnoCare Pharma Ltd is a Chinese clinical-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for the treatment of cancer and autoimmune diseases, prominently featuring novel Bruton's tyrosine kinase (BTK) inhibitors such as orelabrutinib. The company conducts advanced clinical trials evaluating small molecule drugs and biological therapies designed to combat hematological malignancies, solid tumors, and autoimmune disorders. Its core business operations encompass biopharmaceutical research, clinical trial execution, drug formulation development, and commercial pharmaceutical strategy. As a commercial-stage biotechnology enterprise, the company generates revenue through pharmaceutical product sales and collaborative research licensing agreements. InnoCare Pharma holds a leading market position in targeted oncology and immunology therapeutics in China. The company is headquartered in Beijing, China, with corporate registration in the Cayman Islands, and its shares trade on the Stock Exchange of Hong Kong.

4 of the funds FundTelligence covers report a position in Innocare Pharma.

Legal name
Innocare Pharma Ltd
Sector
Health Care
Country
China
Funds holding it
4

Funds holding Innocare Pharma

Loading...